They were not paid and they did not underwrite funding last year, Oppenheimer did. Some brokerage firms may have been allowed very small allocations through syndications but analysts of well respected firms are not paid to do biased reports. This was an internal report made for brokers.
Vtgn trades great volume, any positive data from phase 2 results will create fireworks with PPS.
New improved patents, FDA fast track designation and a rock solid management team.
We dont usually lay 7 figures on low cap biotech’s but this company is in the right place at the right time with the right drugs
News 
Market Data 
Discover 
